Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5863 in CLDN18.2-positive advanced or metastatic solid tumors
CTR20233749Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of HBM7022 in gastric cancer (GC), gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma (PDAC), esophageal adenocarcinoma (EAC), sponsored by AstraZeneca. Started Jul 2024; status: active.
02
Drugs
HBM7022
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinomapancreatic adenocarcinoma (PDAC)esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on CTR20233749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233749.